Cibus, Inc.

Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to Calyxt's fourth quarter 2020 results conference call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be open for questions. If you have a question, please press the star key followed by 1 on your touchtone phone. If you would like to withdraw your question, please press the star key followed by the 2. If you are using speaker equipment, please lift the handset before making your selections. This conference is being recorded today, March 4th, 2021. At this time, I would like to turn the conference over to Chris Tyson, Executive Vice President of MZ North America Calyxt Investor Relations Firm. Please go ahead, sir.

Thank you, and good afternoon. I would like to thank you all for taking time to join us for Kalix's fourth quarter and full year 2020 financial results conference call. Your hosts today are Dr. Eve Rebay, Executive Chair of the Board, and Bill Koshek, Chief Financial Officer. A press release detailing these results crossed the wires after the market closed today and is available on the company's website, Calyxt.com. Before we begin the formal presentation, I'd like to remind everyone that statements made on the call and webcast, including those regarding future financial results and future operational goals and industry prospects, are forward-looking and may be subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the call. Thank you for joining us. and should not be considered a substitute for results that are presented in accordance with GAAP. Finally, this conference call is being webcast. This webcast link is available in the investor relations section of Calyxt.com. At this time, I would like to turn the call over to Calyxt Executive Chair of the Board, Yves Révé. Yves, the floor is yours.

Thank you, Chris, and thank you for joining us today for Calyxt's fourth quarter conference call. I'm sure many of you on today's call who have been following the Calyxt story as a shareholder, prospective investor or analyst have known my roles at Calyxt as a board member since 2018, then interim CEO for a period of time in 2018, and most recently in the summer of 2020, I was appointed to the position of chairman of the board. My background includes a long career in biotech, including founding Sanexis, and more than 25 years in large pharmaceutical companies. I'm currently the Chief Executive Officer of Ribogenics, Inc., which is a private biotechnology company working on RNA biology. Two weeks ago, we announced the transition of my role to Executive Chair replacing CEO Gene Blom. I think it is important to note that our decision in 2020 to transition our business model was one of the primary reasons for the leadership change. Our decision represents a continuing step to focus Calyxt on significant innovations opportunities beyond commodity-based agriculture. We have retained a premier executive search firm and I will help guide the CEO search on behalf of the board and support the transition once the incoming CEO is selected. On behalf of the board, we want to thank Jim for guiding Calyxt to a streamlined business model that can capitalize on delivering disruptive plant-based innovation. Calyxt has experienced a strong and productive 2020. We have redirected Calyxt's innovation engine to new and high-value opportunities and have built a team with the right talent mix to drive Calyxt's go-to-market strategies. We are solidly positioned for future growth and success. I'm excited to work directly with this excellent leadership team during this interim period. I'm also excited to announce the formation of Calyxt Scientific Advisory Board. We previously announced that the SIB will report to the Board of Directors of Calyxt and will be chaired by Dr. Dan Bortas. In addition to Dan, there will initially be three members, all of whom are world-renowned biochemistry experts, and include Dr. Anne Osborne, group leader at the John Innes Center, Dr. Elizabeth Satterley, HHMI investigator and associate professor of chemical engineering at Stanford University, and Dr. Paul Bernasconi, former global function head for molecular biology at BISF Biosciences. The Scientific Advisories Board is tasked with the strategic mission of helping Calyxt identify disruptive, plan-based solutions that are near-term opportunities as well as long-term, higher risk, higher return ideas, some of which may be realized through partnership with other commercial entities. I believe this is an exciting time for Calyxt and our rapidly developing disruptive plant-based technology story. Calyxt is a technology company focused on delivering plant-based innovations to end-users across industry, including food, nutraceutical energy, and agriculture. We see our technology being applicable to other industries as well. We leverage differentiated technologies, including the talent gene editing platform, to develop product candidates. We are a leader in gene editing with exclusive access to proprietary talent technologies for use in plants, which we use to successfully commercialize the first gene editing food product in the U.S. We have a development pipeline that spans multiple crops and has a substantial total addressable market of $8.8 billion. The products in the pipeline will be commercialized through partners and are targeted at critical industry dynamics, including consumer demand for specialty ingredients and supporting sustainability objectives. We also believe that we have a capital-efficient business model with multiple routes to market for our product candidates. I would now like to hand the presentation over to our CFO, Bill Koshak, who will share our 2020 highlights and walk you through our financial performance. Bill?